VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ HBeAg negative within six months prior to          │ HBeAg negative within six months prior to          │     100 │
│ initiation of peginterferon alfa-2a                │ initiation of peginterferon alfa-2a                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HBV DNA \< 200 IU/ml during nucleos(t)ide analogue │ HBV DNA < 200 IU/ml during nucleos(t)ide analogue  │     100 │
│ (except Telbivudine) treatment within one month    │ (except Telbivudine) treatment within one month    │         │
│ prior to initiation of peginterferon alfa-2a       │ prior to initiation of peginterferon alfa-2a       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Compensated liver disease                          │ Compensated liver disease                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Written informed consent                           │ Written informed consent                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with any investigational drug within 30  │ Treatment with any investigational drug within 30  │     100 │
│ days of entry to this protocol                     │ days of entry to this protocol                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current treatment with Telbivudine                 │ Current treatment with Telbivudine                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of decompensated cirrhosis (defined as     │ History of decompensated cirrhosis (defined as     │     100 │
│ jaundice in the presence of cirrhosis, ascites,    │ jaundice in the presence of cirrhosis, ascites,    │         │
│ bleeding gastric or esophageal varices or          │ bleeding gastric or esophageal varices or          │         │
│ encephalopathy)                                    │ encephalopathy)                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Co-infection with hepatitis C virus, hepatitis D   │ Co-infection with hepatitis C virus, hepatitis D   │     100 │
│ virus or human immunodeficiency virus (HIV)        │ virus or human immunodeficiency virus (HIV)        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other acquired or inherited causes of liver        │ Other acquired or inherited causes of liver        │     100 │
│ disease: alcoholic liver disease, obesity induced  │ disease: alcoholic liver disease, obesity induced  │         │
│ liver disease, drug related liver disease, auto-   │ liver disease, drug related liver disease, auto-   │         │
│ immune hepatitis, hemochromatosis, Wilson's        │ immune hepatitis, hemochromatosis, Wilson's        │         │
│ disease or alpha-1 antitrypsin deficiency          │ disease or alpha-1 antitrypsin deficiency          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hyper- or hypothyroidism (subjects requiring       │ Hyper- or hypothyroidism (subjects requiring       │     100 │
│ medication to maintain TSH levels in the normal    │ medication to maintain TSH levels in the normal    │         │
│ range are eligible if all other                    │ range are eligible if all other                    │         │
│ inclusion/exclusion criteria are met)              │ inclusion/exclusion criteria are met)              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Immune suppressive treatment within the previous 6 │ Immune suppressive treatment within the previous 6 │     100 │
│ months                                             │ months                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contra-indications for alfa-interferon therapy     │ Contra-indications for alfa-interferon therapy     │     100 │
│ like suspected hypersensitivity to interferon or   │ like suspected hypersensitivity to interferon or   │         │
│ Peginterferon or any known pre-existing medical    │ Peginterferon or any known pre-existing medical    │         │
│ condition that could interfere with the patient's  │ condition that could interfere with the patient's  │         │
│ participation in and completion of the study       │ participation in and completion of the study       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy, breast-feeding                          │ Pregnancy, breast-feeding                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other significant medical illness that might       │ Other significant medical illness that might       │     100 │
│ interfere with this study: significant pulmonary   │ interfere with this study: significant pulmonary   │         │
│ dysfunction in the previous 6 months, malignancy   │ dysfunction in the previous 6 months, malignancy   │         │
│ other than skin basocellular carcinoma in previous │ other than skin basocellular carcinoma in previous │         │
│ 5 years, immunodeficiency syndromes (e.g. HIV      │ 5 years, immunodeficiency syndromes (e.g. HIV      │         │
│ positivity, auto-immune diseases, organ            │ positivity, auto-immune diseases, organ            │         │
│ transplants other than cornea and hair transplant) │ transplants other than cornea and hair transplant) │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any medical condition requiring, or likely to      │ Any medical condition requiring, or likely to      │     100 │
│ require chronic systemic administration of         │ require chronic systemic administration of         │         │
│ steroids, during the course of the study           │ steroids, during the course of the study           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any other condition which in the opinion of the    │ Any other condition which in the opinion of the    │     100 │
│ investigator would make the patient unsuitable for │ investigator would make the patient unsuitable for │         │
│ enrollment, or could interfere with the patient    │ enrollment, or could interfere with the patient    │         │
│ participating in and completing the study          │ participating in and completing the study          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age \> 18 years                                    │ Age > 18 years                                     │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Alpha fetoprotein \> 50 ng/ml                      │ Alpha fetoprotein > 50 ng/ml                       │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic hepatitis B (HBsAg positive \> 6 months)   │ Chronic hepatitis B (HBsAg positive > 6 months)    │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe hepatitis activity as documented by ALT\>10 │ Severe hepatitis activity as documented by ALT>10  │      99 │
│ x ULN                                              │ x ULN                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pre-existent neutropenia (neutrophils \<1,500/mm3) │ Pre-existent neutropenia (neutrophils <1,500/mm3)  │      99 │
│ or thrombocytopenia (platelets \< 90,000/mm3)      │ or thrombocytopenia (platelets < 90,000/mm3)       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Substance abuse, such as alcohol (\>80 g/day),     │ Substance abuse, such as alcohol (>80 g/day), I.V. │      99 │
│ I.V. drugs and inhaled drugs in the past 2 years   │ drugs and inhaled drugs in the past 2 years        │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria   │   Score │
╞═══════════════════════════════════╪═════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Age > 18 years  │      47 │
╘═══════════════════════════════════╧═════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 97.30434782608695
OverAll Ratio: 98.15217391304347
